Evista Sales Data
| Rank 92 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Evista U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 92 ( 11) |
$196,929 | -4.31% | 776 | -4.55% |
| Q3 2013 | 81 (2) |
$205,790 | 2.22% | 813 | -4.24% |
| Q2 2013 | 79 ( 5) |
$201,330 | 1.91% | 849 | -3.30% |
| Q1 2013 | 84 (5) |
$197,559 | 4.03% | 878 | -4.25% |
| Q4 2012 | 89 (4) |
$189,910 | 0.28% | 917 | -3.07% |
| Q3 2012 | 85 (7) |
$189,378 | 9.53% | 946 | 9.62% |
| Q2 2012 | 92 ( ) |
$172,894 | n/a | 863 | n/a |
| Q4 2011 | 95 (11) |
$168,353 | -4.69% | 905 | -2.06% |
| Q3 2011 | 84 (3) |
$176,642 | -2.26% | 924 | -4.25% |
| Q2 2011 | 87 (4) |
$180,730 | 2.43% | 965 | -3.50% |
| Q1 2011 | 91 | $176,440 | n/a | 1,000 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
